Searched for
PHARMA
NATCO Pharma subsidiary launches Carboplatin in US market to address shortagesIndian pharmaceutical company NATCO Pharma annouced the launch of Carboplatin Injection, a generic version of Paraplatin in the US market b...- Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select playersIndia's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...
- Time to engage smartly with China: Push premium Indian exportsPiyush Goyal has articulated a vision for recalibrating India's economic ties with China, focusing on balanced trade. Both nations are enga...
- Vedanta Power and Cupid among top 5 smallcap stocks that saw highest mutual fund buying in SeptemberFive smallcap stocks saw the highest net buying by mutual funds in September, according to Motilal Oswal Financial Services. Cupid led the ...
- Stocks in news: RIL, Wipro, Jio Financial, Tata Communications, YES Bank, PNBFrom a technical perspective, the 23,000–23,100 zone remains an immediate resistance level for the Nifty, according to Ponmudi R, CEO of En...
- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
- Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- No love for the middle: CPHI Milan exposes India’s pharma scaling challengeIndian pharma and chemical companies at CPHI Milan say the China+1 opportunity is real, but a “missing middle” in the MSME ecosystem, marke...
- Sensex falls over 250 points, Nifty closes below 22,650 even as IT stocks shine. What lies ahead for Dalal Street?Indian equities traded nearly flat after a sharp rally in the previous session, with IT stocks extending gains while pharma shares declined...
- JioBlackRock Flexi Cap Fund exits Eternal, Ashok Leyland and 16 more, trims stake in RIL, HDFC Bank and 32 othersJioBlackRock Flexi Cap Fund made complete exits from 18 stocks, including Eternal and Ashok Leyland, in September 2026, while trimming stak...
- Biocon founder Kiran Mazumdar Shaw says India must shift pharma industry from generics to innovation-led growthKiran Mazumdar-Shaw emphasized the importance of building an innovation-driven pharmaceutical industry in India. She highlighted the need f...
- Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watchIndia's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabil...
- NuSynth Technologies raises Rs 36.5 crore in round led by Avaana Capital, Shastra VCThe company is developing a platform to find simpler, cheaper and more efficient ways to make chemicals, said cofounders Poorvank Purohit a...
- Indian pharma's risk aversion holding back innovation: Kiran Mazumdar-ShawBiocon chairperson Kiran Mazumdar-Shaw calls for greater use of digital technology to speed up drug development, as industry leaders push f...
- Experiments on animals set to become easierThe Centre plans to significantly change the regulations governing animal experimentation. The proposed rules aim to allow institutional et...
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- Anupam Rasayan eyes US, Europe pharma push after Bliss deal, one-third revenue from drugsAnupam Rasayan India Ltd anticipates significant growth in its pharmaceutical segment over the next three years. The company expects pharma...
- Indian SME pharma firms see shift of orders from China; cost, quality concerns remainSmall and mid-sized Indian pharmaceutical firms are witnessing a shift in orders away from China. As Western buyers diversify their supply ...
Load More
